Literature DB >> 24169825

Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation-loop mutation.

Eric Keil1, David Finkenstädt, Christian Wufka, Mirko Trilling, Pia Liebfried, Birgit Strobl, Mathias Müller, Klaus Pfeffer.   

Abstract

Janus kinases (Jak) play essential roles in cytokine and growth factor signaling. Conventional gene targeting of Jak2, creating a null allele, leads to a block in definitive erythropoiesis as a result of failing signal transduction at the homomeric erythropoietin receptor (EpoR) and at the heteromeric interferon γ receptor (IFNGR). To investigate the in vivo relevance of the activation loop of Jak2, a Jak2-YY1007/1008FF knockin mutation was introduced into the germline of mice. The phenotype of the Jak2(FF/FF) mouse line reveals that tyrosine residues 1007/1008 are absolutely essential for kinase function and signal transduction at the homomeric EpoR. Detailed studies using the Jak2 activation loop mutant uncover an essential scaffolding function of Jak2 within the IFNGR receptor complex and reveal that Jak1 can mediate a semi-redundant function for IFNGR signal transduction. These studies are highly important for the molecular understanding of cytokine and growth factor signaling and provide new insights for future strategies in the design of pharmacological blockers of Jak2.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24169825     DOI: 10.1182/blood-2013-03-492157

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.

Authors:  Henrik M Hammarén; Anniina T Virtanen; Bobin George Abraham; Heidi Peussa; Stevan R Hubbard; Olli Silvennoinen
Journal:  J Allergy Clin Immunol       Date:  2018-08-06       Impact factor: 10.793

2.  An activity-dependent determinant of synapse elimination in the mammalian brain.

Authors:  Masahiro Yasuda; Sivapratha Nagappan-Chettiar; Erin M Johnson-Venkatesh; Hisashi Umemori
Journal:  Neuron       Date:  2021-03-25       Impact factor: 17.173

3.  JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.

Authors:  Paolo Gallipoli; Amy Cook; Susan Rhodes; Lisa Hopcroft; Helen Wheadon; Anthony D Whetton; Heather G Jørgensen; Ravi Bhatia; Tessa L Holyoake
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

4.  Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.

Authors:  E Grundschober; A Hoelbl-Kovacic; N Bhagwat; B Kovacic; R Scheicher; E Eckelhart; K Kollmann; M Keller; F Grebien; K U Wagner; R L Levine; V Sexl
Journal:  Leukemia       Date:  2014-05-05       Impact factor: 11.528

Review 5.  Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses.

Authors:  Andrea Majoros; Ekaterini Platanitis; Elisabeth Kernbauer-Hölzl; Felix Rosebrock; Mathias Müller; Thomas Decker
Journal:  Front Immunol       Date:  2017-01-26       Impact factor: 7.561

6.  Loss of JAK1 Drives Innate Immune Deficiency.

Authors:  Agnieszka Witalisz-Siepracka; Klara Klein; Daniela Prinz; Nicoletta Leidenfrost; Gernot Schabbauer; Alexander Dohnal; Veronika Sexl
Journal:  Front Immunol       Date:  2019-01-08       Impact factor: 7.561

7.  The SH2 domain and kinase activity of JAK2 target JAK2 to centrosome and regulate cell growth and centrosome amplification.

Authors:  Aashirwad Shahi; Jacob Kahle; Chandler Hopkins; Maria Diakonova
Journal:  PLoS One       Date:  2022-01-28       Impact factor: 3.752

8.  Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation.

Authors:  Samadhi Aparicio-Siegmund; Jan Sommer; Niloufar Monhasery; Ralf Schwanbeck; Eric Keil; David Finkenstädt; Klaus Pfeffer; Stefan Rose-John; Jürgen Scheller; Christoph Garbers
Journal:  Oncotarget       Date:  2014-04-30

9.  TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis.

Authors:  Eric Gracey; Dominika Hromadová; Melissa Lim; Zoya Qaiyum; Michael Zeng; Yuchen Yao; Archita Srinath; Yuriy Baglaenko; Natalia Yeremenko; William Westlin; Craig Masse; Mathias Müller; Birgit Strobl; Wenyan Miao; Robert D Inman
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

10.  Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling.

Authors:  Juuli Raivola; Teemu Haikarainen; Olli Silvennoinen
Journal:  Cancers (Basel)       Date:  2019-12-27       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.